Rapid ART initiation is defined by the WHO as within 7 days of diagnosis, and as early as the same day. Many guidelines, including those from China, the European Union, the United Kingdom, the United States and the WHO, recommend against using NNRTIs for rapid ART initiation owing to concerns about potential drug resistance. Appropriate first-line regimens may include combinations of ARV drugs from the following classes: NRTIs, INSTIs and/or protease inhibitors.
Although the results of drug resistance testing are important to guide therapy in patients who are ARV-naive, as well as in patients in whom first- or second-line regimens produce a suboptimal virologic response or virologic failure, this testing should not delay the initiation of ART. The regimen may be adjusted as needed once the results are known.
Learn more about the management of drug-resistant HIV.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Michael Stuart Bronze, Enrico Brunetti. Fast Five Quiz: Treatment-Resistant HIV - Medscape - Aug 14, 2023.